Treatments according to lesion dissemination
| . | Localized (n = 426, 71.8%) . | Disseminated (n = 167, 28.2%) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Stage I . | Stage II . | Stage III-IV . | ||||||
| A single lesion (involvement) in extranodal site (n = 375) . | Multifocal involvement of a single/pared extranodal site∗ (n = 13) . | One site + regional LN(s) (n = 38) . | Multiple distant skin involvement (n = 51) . | Bilateral lung involvement (n = 17) . | A single site + nonlocoregional nodes/BM involvement (n = 36) . | MMS involvement (n = 35) . | Multiple sites + LN(s) (n = 28) . | |
| Observation | 45 (12.0) | 1 (7.7) | 6 (15.8) | 22 (43.1) | 10 (58.8) | 12 (33.3) | 9 (25.7) | 8 (28.6) |
| Local treatment | ||||||||
| Total | 308 (82.1) | 10 (76.9) | 22 (57.9) | 23 (45.1) | 4 (23.5) | 5 (13.9) | 10 (28.6) | 4 (14.3) |
| RT | 185 (49.3) | 6 (46.2) | 11 (28.9) | 9 (17.6) | 0 | 1 (2.8) | 7 (20.0) | 3 (10.7) |
| Surgery | 105 (28.0) | 2 (15.4) | 8 (21.1) | 3 (5.9) | 4 (23.5) | 3 (8.3) | 2 (5.7) | 1 (3.6) |
| Site specific | 18 (4.8) | 2 (15.4) | 3 (7.9) | 11 (21.6) | 0 | 1 (2.8) | 1 (2.9) | 0 |
| Systemic treatment | ||||||||
| Total | 22 (5.9) | 2 (15.4) | 10 (26.3) | 6 (11.8) | 3 (17.6) | 19 (52.8) | 16 (45.7) | 16 (57.1) |
| Anti-CD20 antibody | 16 (4.3) | 1 (7.7) | 2 (5.3) | 3 (5.9) | 1 (5.9) | 7 (19.4) | 10 (28.6) | 7 (25.0) |
| Chemoimmunotherapy | 6 (1.6) | 1 (7.7) | 8 (21.1) | 3 (5.9) | 2 (11.8) | 12 (33.3) | 6 (17.1) | 9 (32.1) |
| . | Localized (n = 426, 71.8%) . | Disseminated (n = 167, 28.2%) . | ||||||
|---|---|---|---|---|---|---|---|---|
| Stage I . | Stage II . | Stage III-IV . | ||||||
| A single lesion (involvement) in extranodal site (n = 375) . | Multifocal involvement of a single/pared extranodal site∗ (n = 13) . | One site + regional LN(s) (n = 38) . | Multiple distant skin involvement (n = 51) . | Bilateral lung involvement (n = 17) . | A single site + nonlocoregional nodes/BM involvement (n = 36) . | MMS involvement (n = 35) . | Multiple sites + LN(s) (n = 28) . | |
| Observation | 45 (12.0) | 1 (7.7) | 6 (15.8) | 22 (43.1) | 10 (58.8) | 12 (33.3) | 9 (25.7) | 8 (28.6) |
| Local treatment | ||||||||
| Total | 308 (82.1) | 10 (76.9) | 22 (57.9) | 23 (45.1) | 4 (23.5) | 5 (13.9) | 10 (28.6) | 4 (14.3) |
| RT | 185 (49.3) | 6 (46.2) | 11 (28.9) | 9 (17.6) | 0 | 1 (2.8) | 7 (20.0) | 3 (10.7) |
| Surgery | 105 (28.0) | 2 (15.4) | 8 (21.1) | 3 (5.9) | 4 (23.5) | 3 (8.3) | 2 (5.7) | 1 (3.6) |
| Site specific | 18 (4.8) | 2 (15.4) | 3 (7.9) | 11 (21.6) | 0 | 1 (2.8) | 1 (2.9) | 0 |
| Systemic treatment | ||||||||
| Total | 22 (5.9) | 2 (15.4) | 10 (26.3) | 6 (11.8) | 3 (17.6) | 19 (52.8) | 16 (45.7) | 16 (57.1) |
| Anti-CD20 antibody | 16 (4.3) | 1 (7.7) | 2 (5.3) | 3 (5.9) | 1 (5.9) | 7 (19.4) | 10 (28.6) | 7 (25.0) |
| Chemoimmunotherapy | 6 (1.6) | 1 (7.7) | 8 (21.1) | 3 (5.9) | 2 (11.8) | 12 (33.3) | 6 (17.1) | 9 (32.1) |
LN, lymph node.
Excluding bilateral lungs and multiple distant skin involvement (classified as stage IV, whereas bilateral organ involvement in other anatomical sites is defined as stage I disease).